Lanton Law PLLC

Reclaiming mRNA's Story: How U.S. Policy Upheavals Are Pushing Us To Adapt Is The mRNA Payload The Real MVP Of Targeted Delivery?

Explore CQA analysis solutions for mRNA biotherapeutics Get full access to our comprehensive application compendium, featuring a collection of resources showcasing how Agilent automated electrophoresis and LC/MS solutions can support reliable CQA analysis throughout your IVT mRNA-based biotherapeutic workflow. Get your copy. With HHS winding down mRNA vaccine development under BARDA, could Europe seize the opportunity to lead in mRNA innovation? Exploring the policy shift's implications.

By Ron Lanton III, Esq., Lanton Law PLLC With the unprecedented success of mRNA vaccines during the pandemic, it almost felt as though mRNA technology was about to enter a “golden era” where new solutions using this platform would be found to finally address costly and devastating diseases that had been wreaking havoc in many countries.